Quipt Home Medical Announces Voting Results From Special Meeting of Shareholders
Rhea-AI Summary
Quipt Home Medical (NASDAQ: QIPT) announced that shareholders approved a court‑supervised plan of arrangement to be acquired for US$3.65 per share. The special meeting on March 3, 2026 recorded 29,672,136 shares (≈66.93%) represented and strong support for the resolution.
The Company will seek a final order from the Supreme Court of British Columbia on March 5, 2026; completion remains subject to exchange and regulatory approvals.
Positive
- Acquisition price of US$3.65 per share
- Shareholder approval: 98.9% of votes cast in favor
- 66.93% (29,672,136 shares) represented at the meeting
Negative
- Arrangement requires Supreme Court of British Columbia final order on March 5, 2026
- Completion contingent on stock exchange and regulatory approvals
Key Figures
Market Reality Check
Peers on Argus
Two sector peers in the momentum scanner moved down (median about -3.1%), while QIPT’s price was unchanged, pointing to stock-specific trading anchored to the $3.65 cash deal rather than sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Deal documentation | Positive | +0.1% | Definitive proxy circular and interim court order for <b>$3.65</b> arrangement. |
| Dec 15 | Take-private agreement | Positive | +34.1% | Definitive cash acquisition agreement at <b>$3.65</b> per share, <b>$260M</b> value. |
| Dec 15 | Earnings results | Positive | +34.1% | Strong Q4/FY2025 growth and margins alongside pending buyout announcement. |
| Dec 05 | Activist campaign | Neutral | +2.5% | Shareholder publicly urged board to pursue a value-maximizing sale process. |
| Sep 03 | M&A acquisition | Positive | +1.2% | Completion of Hart Medical acquisition adding <b>$60M</b> revenue and EBITDA growth. |
News tied to the $3.65 take‑private transaction and strategic acquisitions has generally been followed by positive, deal-aligned price moves.
Over the past six months, Quipt’s trajectory has been dominated by its planned sale for $3.65 per share. The definitive agreement and FY2025 results on Dec 15, 2025 coincided with a sharp positive move. Subsequent filings, including the proxy and interim court order on Feb 4, 2026, further advanced the process. Earlier, Quipt expanded via Hart Medical’s acquisition, adding $60M revenue. Today’s shareholder approval vote continues this pattern of transaction milestones steadily progressing toward closing the going‑private deal.
Market Pulse Summary
This announcement confirms strong shareholder backing for Quipt’s cash acquisition at $3.65 per share, with up to 98.9% approval overall and 98.7% support from minority holders under MI 61‑101. It follows earlier filings detailing the arrangement structure and required thresholds of at least 66⅔% of votes cast. Investors tracking this situation would focus on the scheduled March 5, 2026 court hearing and remaining regulatory conditions as the transaction advanced toward potential completion.
Key Terms
plan of arrangement regulatory
business corporations act (british columbia) regulatory
multilateral instrument 61-101 regulatory
form 8-k regulatory
proxy statement regulatory
management information circular regulatory
AI-generated analysis. Not financial advice.
CINCINNATI, March 03, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its special meeting of holders (the “Shareholders”) of common shares (the “Shares”) of the Company held on March 3, 2026 (the “Meeting”) in Sarasota, Florida. The Shareholders voted to approve the special resolution (the “Arrangement Resolution”) approving the plan of arrangement under the Business Corporations Act (British Columbia), involving, among other things, the acquisition by affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC of all of the issued and outstanding Shares (the “Arrangement”) for cash consideration of US
The Arrangement Resolution required approval of: (i) at least 66⅔% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting; and (ii) in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”), a simple majority of votes cast by the Shareholders, present in person or represented by proxy and entitled to vote at the Meeting, excluding the votes in respect of Shares cast by any “interested party”, any “related party” of an “interested party” or any “joint actor” (as such terms are defined in MI 61-101). Shareholders holding 29,672,136 Shares, representing approximately
The Company is scheduled to seek a final order of the Supreme Court of British Columbia approving the Arrangement on March 5, 2026. Assuming all other terms and conditions, including applicable stock exchange and regulatory approvals, to the Arrangement are satisfied, it is expected that the Arrangement will be completed in the near term. Further information about the Arrangement can be found in the Company’s definitive proxy statement and management information circular dated January 23, 2026 for the Meeting, which is available under the Company’s profile on SEDAR+ and on the Company’s website https://quipthomemedical.com., and has been filed with the SEC on the EDGAR website at www.sec.gov.
A Form 8-K in respect of the voting results has been filed with the SEC on the EDGAR website at www.sec.gov, on SEDAR+ under the Company’s issuer profile at www.sedarplus.com.
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “postulate”, “expect”, “outlook”, or the negatives thereof or variations of such words, and similar expressions as they relate to the Company are intended to identify forward-looking statements, including: the proposed Arrangement and terms thereof; and the anticipated completion of the Arrangement, including receipt of court and regulatory approval and satisfaction of closing conditions; and other statements that are not historical fact. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the ability to obtain the necessary regulatory, court, and other third party approvals for the Arrangement, the timing of obtaining such approvals and the risk that such approvals may not be obtained in a timely manner or at all, and the risk that such approvals may be obtained on conditions that are not anticipated; the timing of closing of the Arrangement; the risk that the conditions to the Arrangement are not satisfied on a timely basis or at all and the failure of the Arrangement to close for any other reason; the delisting of the Shares from the TSX and NASDAQ; the Company ceasing to be a reporting issuer under Canadian and U.S. federal securities laws and the timing thereof; the abilities of the parties to satisfy, in a timely manner, the other conditions to the closing of the Arrangement; the failure of the Arrangement to close for any other reason; and the ability to achieve the expected benefits of the Arrangement. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the SEC and available on EDGAR at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
For further information please visit our website at www.quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
cole.stevens@myquipt.com
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
investorinfo@myquipt.com
FAQ
What did Quipt (QIPT) shareholders vote on at the March 3, 2026 meeting?
How many Quipt (QIPT) shares were represented at the March 3, 2026 special meeting?
When will Quipt (QIPT) seek court approval to complete the arrangement?
What closing conditions remain for the Quipt (QIPT) transaction after shareholder approval?
Who are the buyers in Quipt's (QIPT) approved arrangement and what is the consideration?
